Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (231-240 of 274) with videos related to

Pageof 28
Sort By:
Cancers|March 28, 2024
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell TransplantationWancheng Guo, Christopher Strouse, David Mery, et al.
Bone Marrow Transplantation|February 16, 2024
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myelomaMeera Mohan, Aniko Szabo, Anannya Patwari, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
American Journal of Hematology|September 13, 2022
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experienceMeera Mohan, Lisa E Rein, Nishanth Thalambedu, et al.
Leukemia|August 8, 2021
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroupsEileen M Boyle, Adam Rosenthal, Hussein Ghamlouch, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Leukemia|April 15, 2018
Kinase domain activation through gene rearrangement in multiple myelomaGareth J Morgan, Jie He, Ruslana Tytarenko, et al.
Ejhaem|July 18, 2022
Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trialNoa Biran, Binod Dhakal, Suzanne Lentzsch, et al.
Genome Research|December 22, 2021
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancersAneta Mikulasova, Daniel Kent, Marco Trevisan-Herraz, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
Pageof 28

Showing results (231-240 of 274) with videos related to

Sort By:
Pageof 28
Cancers|March 28, 2024
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell TransplantationWancheng Guo, Christopher Strouse, David Mery, et al.
Bone Marrow Transplantation|February 16, 2024
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myelomaMeera Mohan, Aniko Szabo, Anannya Patwari, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
American Journal of Hematology|September 13, 2022
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experienceMeera Mohan, Lisa E Rein, Nishanth Thalambedu, et al.
Leukemia|August 8, 2021
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroupsEileen M Boyle, Adam Rosenthal, Hussein Ghamlouch, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Leukemia|April 15, 2018
Kinase domain activation through gene rearrangement in multiple myelomaGareth J Morgan, Jie He, Ruslana Tytarenko, et al.
Ejhaem|July 18, 2022
Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trialNoa Biran, Binod Dhakal, Suzanne Lentzsch, et al.
Genome Research|December 22, 2021
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancersAneta Mikulasova, Daniel Kent, Marco Trevisan-Herraz, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
Pageof 28